ETHLAD

ETH-LAD is a psychedelic drug in the lysergamide family, a structural analog of lysergic acid diethylamide (LSD). It is one of several lysergamide derivatives reported to produce LSD-like effects, with reports suggesting higher potency and a similar spectrum of perceptual and cognitive alterations. The name ETH-LAD reflects its chemical modification of the amide group relative to LSD, though specific pharmacological details are not as well established in peer-reviewed literature.

In user reports and early toxicology references, ETH-LAD produces intense visual effects, mood elevation, and altered thought processes, with onset typically within 1 hour after ingestion, peak effects in the 2-4 hour range, and a total duration longer than LSD, often around 8-12 hours. As with other lysergamides, its effects are highly dose-dependent and can be influenced by set and setting.

Pharmacology is not fully characterized in clinical studies; it is presumed to act as a 5-HT2A receptor agonist, producing psychedelic effects, with possible activity at other serotonin receptors. Safety concerns include the potential for anxiety, paranoia, vasoconstriction, and cardiovascular effects, particularly at high doses or in susceptible individuals.

Legal status varies by country and jurisdiction; ETH-LAD is controlled or illegal in several places as a scheduled substance or under analogue laws, while some jurisdictions have broader prohibitions on lysergamides. As with other potent psychedelics, research and handling should be considered carefully, and unregulated use carries health risks.